Arcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call Transcript
Arcus Biosciences, Inc. (RCUS) Q1 2026 Earnings Call Transcript
RCUS - Arcus Biosciences, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$31.17
DETAILS
HIGH:
$47.00
LOW:
$22.00
MEDIAN:
$30.00
CONSENSUS:
$31.17
UPSIDE:
33.03%
Stock News
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.14 per share a year ago.
Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026 and provided a pipeline update on its clinical-stage investigational molecules and discovery programs. “Arcus is entering a new era, with a clear path for casdatif.
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 4,200 shares of the Company's common stock at an exercise price per share of $25.13, which was the.
What's Going On With Arcus Biosciences Stock On Wednesday?
Cancer-focused biotech, Arcus Biosciences, Inc. (NYSE:RCUS) stock is trading higher on Wednesday after the company's stock closed lower on Tuesday following a lung cancer trial update.
Arcus Biosciences (RCUS) Moves 7.8% Higher: Will This Strength Last?
Arcus Biosciences (RCUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will host a conference call and webcast on Tuesday, May 5, 2026 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline updates for the quarter ended March 31st, 2026. In.
Financial Analysis: Arcus Biosciences (NYSE:RCUS) vs. Immunovant (NASDAQ:IMVT)
Arcus Biosciences (NYSE: RCUS - Get Free Report) and Immunovant (NASDAQ: IMVT - Get Free Report) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, profitability and earnings. Institutional and Insider Ownership 92.9% of Arcus Biosciences
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 7,850 shares of the Company's common stock at an exercise price per share of $22.65, which was the.
Arcus Biosciences (NYSE:RCUS) Trading Up 5.4% Following Analyst Upgrade
Arcus Biosciences, Inc. (NYSE: RCUS - Get Free Report) shares were up 5.4% on Thursday after Wedbush raised their price target on the stock from $37.00 to $41.00. Wedbush currently has an outperform rating on the stock. Arcus Biosciences traded as high as $22.59 and last traded at $23.0270. Approximately 293,340 shares were traded during mid-day
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms.
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune disorders, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 7,050 shares of the Company's common stock at an exercise price per share of $21.41, which was th.
Arcus Biosciences Announces New Employment Inducement Grants
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 17,050 shares of the Company's common stock at an exercise price per share of $23.43, which was th.
Arcus Biosciences: Q4 Beat And Casdatifan's Story So Far
Arcus Biosciences posted strong FY25 results, beating EPS and revenue estimates despite no commercial products and heavy R&D investment. RCUS's valuation premium is driven by Casdatifan, a next-generation HIF-2α inhibitor showing superior efficacy and safety versus competitors in ccRCC. The company's $1.01B cash position funds operations into at least 2H28, supporting multiple Phase 3 programs and mitigating near-term financing risk.
Arcus Biosciences, Inc. (RCUS) Q4 2025 Earnings Call Transcript
Arcus Biosciences, Inc. (RCUS) Q4 2025 Earnings Call Transcript
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, today reported financial results for the year and quarter ended December 31, 2025, and provided a pipeline update on its clinical-stage investigational molecules and discovery programs. “This week's updated data at ASCO GU continue to va.
Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases, today announced a new analysis of efficacy and biomarker data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in late-line metastatic clear cell renal cell carcinoma (ccRCC) from the Phase 1/1b ARC-20 study. These data will be presented in a post.
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will host a conference call and webcast on Wednesday, February 25th, 2026 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company's financial results and pipeline update for the quarter and year ended De.
Rapid Innovation is Reshaping Oncology: Stocks in Focus
Rapid advances in immunotherapy, targeted drugs & artificial intelligence-driven research are reshaping oncology, spotlighting select cancer stocks to watch now.
Price Targets
Arcus Biosciences assumed with a Buy at Truist
$35.00
(was $23.78)
Truist Financial
Arcus Biosciences price target raised to $22 from $20 at Morgan Stanley
$22.00
(was $25.32)
Morgan Stanley
Arcus Biosciences price target lowered to $47 from $49 at Leerink
$47.00
(was $22.73)
Leerink Partners
Arcus Biosciences downgraded to Equal Weight from Overweight at Wells Fargo
$23.00
(was $21.36)
Wells Fargo
Arcus Biosciences upgraded to Buy from Neutral at Goldman Sachs
$28.00
(was $21.30)
Richard Law
·
Goldman Sachs
Arcus Biosciences downgraded to Equal Weight from Overweight at Morgan Stanley
$20.00
(was $23.20)
Morgan Stanley
Arcus Biosciences price target lowered to $30 from $39 at Truist
$30.00
(was $22.27)
Truist Financial
Arcus Biosciences price target raised to $32 from $28 at H.C. Wainwright
$32.00
(was $22.15)
H.C. Wainwright
Arcus Biosciences price target raised to $16 from $14 at Goldman Sachs
$16.00
(was $20.64)
Salveen Richter
·
Goldman Sachs
Arcus Biosciences price target raised to $35 from $33 at Wedbush
$35.00
(was $20.29)
Wedbush
Arcus Biosciences price target raised to $28 from $24 at H.C. Wainwright
$28.00
(was $19.88)
H.C. Wainwright
Arcus Biosciences price target raised to $39 from $32 at Truist
$39.00
(was $14.48)
Asthika Goonewardene
·
Truist Financial
Arcus Biosciences price target lowered to $26 from $29 at Wells Fargo
$26.00
(was $8.12)
Eva Fortea Verdejo
·
Wells Fargo
Arcus Biosciences price target raised to $46 from $38 at Citi
$46.00
(was $17.41)
Yigal Nochomovitz
·
Citigroup
H.C. Wainwright Starts Arcus Biosciences (RCUS) at Neutral
$20.00
(was $18.44)
Emily Bodnar
·
H.C. Wainwright
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
$35.00
(was $18.08)
Judah Frommer
·
Morgan Stanley
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
$29.00
(was $18.08)
Eva Fortea Verdejo
·
Wells Fargo
Arcus Biosciences (RCUS) PT Lowered to $23 at BofA Securities
$23.00
(was $13.69)
Jason Zemansky
·
Bank of America Securities
Arcus Biosciences (RCUS) PT Lowered to $25 at Barclays
$25.00
(was $14.00)
Peter Lawson
·
Barclays
Arcus Biosciences (RCUS) PT Lowered to $44 at Truist Securities
$44.00
(was $16.45)
Asthika Goonewardene
·
Truist Financial